



Rallybio to Present at Upcoming Investor Conferences in November

November 11, 2022

NEW HAVEN, Conn.--(BUSINESS WIRE)--Nov. 11, 2022-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences:

- **Jefferies London Healthcare Conference** in London, United Kingdom on Tuesday, November 15, 2022, at 8:35 a.m. GMT (3:35 a.m. EST)
- **Evercore ISI 5th Annual HealthCONx Conference** being held virtually on Wednesday, November 30, 2022, at 8:25 a.m. EST.

Live webcasts of both fireside chats will be accessible through the [Events and Presentations](#) section of Rallybio's website at www.rallybio.com. A replay of the webcasts will be available for 30 days following each event.

About Rallybio

Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company's mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut's Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20221109006005/en/): <https://www.businesswire.com/news/home/20221109006005/en/>

Investors

Ami Bavishi
Head of Investor Relations and Corporate Communications
609-477-4536
abavishi@rallybio.com

Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media

Tara DiMilia
908-369-7168
Tara.dimilia@tmstrat.com

Source: Rallybio Corporation